All In Biotech

Drug Trial Radar · NCT01681953

A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis.

Last checked: Nov 20, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

25

Actual

Start

Aug 2012

Primary completion

May 2014

Study completion May 2014

Sponsor

Lead sponsor
Zymenex A/SIndustry
Sponsor type
Industry
Collaborators
European Commission
First posted
Sep 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this trial is to evaluate the efficacy and safety of repeated Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with alpha-Mannosidosis

Conditions

  • Alpha-Mannosidosis

Interventions

  • LamazymDrug

    ERT, i.v. infusions weekly

  • PlaceboDrug

    Infusions weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of oligosaccharides in serumTime frame: Baseline evaluation prior to first dose, midterm evaluation after 26 weeks, and end evaluation after 52 weeks
  2. The number of steps climbed in 3 minutes (3-minute stair climb test)Time frame: Baseline evaluation prior to first dose, midterm evaluation after 26 weeks, and end evaluation after 52 weeks

Locations

6 sites in 5 countries. Site status is shown where the registry gives one.

  • Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9

    Copenhagen, Denmark

  • Hôpital Femme Mère Enfant, Lyon, 59 boulevard Pinel

    Bron, France

  • Hôpital Trousseau, Service de neuropédiatrie, Centre Référence des Maladies Lysosomales, 26 avenue du Docteur Arnold Netter

    Paris, France

  • Universitätsmedizin Mainz, Zentrum für Kinder- und Jugendmedizin, Langenbeckstrasse 1

    Mainz, Germany

  • The Children's Memorial Health Institute Warsaw, Department of Metabolic Diseases, Al Dzieci Polskich 20

    Warsaw, Poland

  • Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.